<DOC>
	<DOCNO>NCT01002274</DOCNO>
	<brief_summary>This open-label extension study another study protocol , MCS-2-TWN-a . Subjects complete 12-week treatment procedure protocol MCS-2-TWN-a eligible study .</brief_summary>
	<brief_title>Open-Label Extension Study MCS-2 Treatment Lower Urinary Tract Symptoms</brief_title>
	<detailed_description>This open-label extension study design ass long-term safety efficacy MCS-2 . Subjects complete 12-week treatment procedure protocol MCS-2-TWN-a eligible another 40 week MCS-2 treatment daily dosage active treatment give protocol MCS-2-TWN-a . Subjects limit currently treat medically BPH LUTS .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<criteria>Subject complete 12 week treatment protocol MCS2TWNa . Subject able understand willing conform study procedure sign informed consent form participation extension study . Subject severe LUTS last visit protocol MCS2TWNa . Subject consider ineligible study investigator ( ) .</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Benign Prostatic Hyperplasia</keyword>
	<keyword>BPH</keyword>
	<keyword>MCS-2</keyword>
	<keyword>Multi-Carotenoids</keyword>
	<keyword>Lower Urinary Tract Symptoms</keyword>
	<keyword>International prostate symptom score</keyword>
</DOC>